TSC Ratings' Updates: Apple

Net operating cash flow has decreased to $1,073.00 million, or 12.47% when compared with the same quarter last year, but Genworth is still fairing well by exceeding its industry average cash flow growth rate of -41.62%. Shares are down 96.1% on the year, underperforming the S&P 500. Naturally, the overall market trend is bound to be a significant factor, and in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

We've downgraded Hologic (HOLX Quote) from hold to sell, driven by its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Net income has significantly decreased by 549.6% since the same quarter a year ago, to -$144.37 million, underperforming both the S&P 500 and the health care equipment and supplies industry. Return on equity has greatly decreased as well, a signal of major weakness within the corporation. Hologic's return on equity significantly trails that of both the industry average and the S&P 500. It has experienced a steep decline of 293.1% in earnings per share in the most recent quarter in comparison with its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years, but the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, Hologic swung to a loss, reporting -$1.76 vs. 87 cents in the prior year. This year, the market expects an mprovement in earnings to $1.23. Its debt-to-equity ratio of 0.47 is low, but it is higher than that of the industry average. The company's quick ratio of 1.25 is sturdy.